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Perioperative Management of Patients With Coronary Stents
Emmanouil S. Brilakis, MD, PHD, FACC,* Subhash Banerjee, MD, FACC,*
Peter B. Berger, MD, FACC†
Dallas, Texas; and Danville, Pennsylvania
Perioperative coronary stent thrombosis is a catastrophic complication that can occur in patients receiving both
bare-metal and drug-eluting stents. Noncardiac surgery appears to increase the risk that recently-placed stents
thrombose, especially when surgery is performed early after stenting, and particularly if dual antiplatelet therapy
is discontinued. We reviewed the existing data about the frequency of stent thrombosis after noncardiac surgery
and explored the impact of delay from surgery and discontinuation of antiplatelet therapy. We also reviewed the
data about the impact of preoperative revascularization in patients known to require noncardiac surgery. Based
on these published data, we offer recommendations that can be used to guide the treatment of patients who
require noncardiac surgery after having received a stent. (J Am Coll Cardiol 2007;49:2145–50) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.046p
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soronary revascularization before noncardiac surgery may
ecrease the perioperative and postoperative risk in selected
atients (1). The number of percutaneous coronary inter-
entions (PCIs) now exceeds the number of coronary artery
ypass surgeries performed each year, and the difference
ontinues to grow. Stents currently are used in the majority
f PCIs because they increase procedural success and
ecrease restenosis (2). A rare but severe complication after
oronary stent implantation is stent thrombosis (3). Stent
hrombosis is associated with a suboptimal angiographic
esult (4–6), specific high-risk lesion characteristics (such as
mall vessels [7–9]and bifurcation lesions [3]), high-risk
atients such as those with diabetes and renal failure (3),
nd, importantly, early cessation of dual antiplatelet therapy
ith aspirin and a thienopyridine (3,10). Obtaining a good
ngiographic result and administering dual antiplatelet ther-
py (11) (currently aspirin and clopidogrel) are the corner-
tones of stent thrombosis prevention.
Noncardiac surgery and most invasive procedures increase
he risk of stent thrombosis, especially when the procedure
s performed early after stent implantation, likely because
tents are not yet endothelialized early after placement,
ecause antiplatelet therapy is often discontinued in the
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007, accepted February 27, 2007.eriprocedural period, and because surgery creates a pro-
hrombotic state (12); this may be particularly true when
one under general anesthesia compared with regional
nesthesia (13). Perioperative stent thrombosis has been
tudied primarily in patients who received bare-metal stents
BMS). There are limited data about the risk of perioper-
tive thrombosis of drug-eluting stents (DES), even though
ES currently are used in 70% to 80% of PCI procedures in
he U.S. Clinicians caring for patients with coronary stents
ho need surgery often have difficulty choosing a treatment
trategy that allows the surgery to be as safe as possible while
inimizing the risk of perioperative stent thrombosis. The
oal of this review is to offer guidance to clinicians by
ummarizing the available data on the incidence, risk
actors, prevention, and treatment of perioperative coronary
tent thrombosis.
isk of Surgery After Stent Implantation
MS. The high risk of surgery early after coronary stenting
as first described in 2000 (14): 8 of the 25 patients
ndergoing noncardiac surgery within 2 weeks of BMS
lacement died (32%, 95% confidence interval (CI) 15 to
4). In contrast, none of the 15 patients who underwent
urgery 15 to 39 days after stenting died. Six of the 8 deaths
ere caused by acute myocardial infarction (AMI) and 2
ere caused by bleeding (14). A total of 7 patents had AMI
hat was probably or definitely caused by stent thrombosis,
nd 6 of them died. Three of the 5 patients who underwent
perations while taking ticlopidine died, 1 from bleeding
nd 2 from AMI and bleeding.
In a much larger population of patients undergoing
urgery within 2 months after receiving a BMS at the Mayo
linic, only 8 of the 207 patients (3.9%, 95% CI 1.7 to 7.5)
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Perioperative Management of Coronary Stents June 5, 2007:2145–50died or suffered an AMI or stent
thrombosis (15). In contrast to the
study by Kaluza et al. (14), the risk
of death, MI, or stent thrombosis
was elevated for 6 weeks, not for
just 2 weeks, and to a much lesser
degree, with the risk during each
of the first 6 weeks ranging from
3.8% to 7.1%; no events occurred
among the 39 patients who under-
went surgery in the 6th through
8th weeks after stent placement.
Another study analyzed the
outcome of 27 patients who un-
derwent noncardiac surgery
ithin 3 weeks after BMS implantation (16). Six of 7
atients (86%), in whom the thienopyridine was stopped for
5 days died (only 1 patient had angiographically docu-
ented stent thrombosis) compared with only 1 of the 20
atients (5%) who underwent noncardiac surgery within 3
eeks from stent implantation and continued to take a
hienopyridine (p  0.001). Among 20 patients undergoing
urgery 3 weeks to 3 months after stenting (70% of whom
ontinued taking a thienopyridine), only 1 patient died
5%), and 2 suffered a non–ST-segment elevation AMI.
In another series, thrombotic events or major bleeding
ccurred in 8 of 16 patients (50%) undergoing noncardiac
urgery within 42 days after receiving a BMS, and in none
f 40 patients who underwent surgery 42 days after
eceiving a BMS (17). Vicenzi et al. (18) reported a 43%
requency of adverse cardiac events in 103 patients under-
oing surgery after stent deployment, but those events were
oorly characterized.
These studies have appropriately increased attention to
he potential risks of surgery early after stent implantation,
nd highlighted the importance of delaying surgery when
ossible and continuing dual antiplatelet therapy in the
erioperative period when surgery is not delayed.
ES. There are limited data about the risk of noncardiac
urgery after DES placement. McFadden et al. (19) re-
orted DES thrombosis in 3 patients undergoing surgery
bladder polyp resection, colon cancer resection, and
olonoscopy with polypectomy) late (343 to 442 days) after
mplantation. Nasser et al. (20) reported sirolimus-eluting
tent (SES) thrombosis in 2 patients after surgery performed
and 21 months after SES implantation.
Compton et al. (21) reported a single-center series of 38
atients who underwent 41 major and 18 minor noncardiac
urgeries a median of 9 months from successful DES
mplantation: no major adverse cardiac events or deaths
ccurred during or after the 41 major (0%, 95% CI 0 to 9%),
nd 18 minor noncardiac surgical procedures (0%, 95% CI
to 19%). Schouten et al. (22) reported that stent throm-
osis occurred in 3 of 99 (3%) patients undergoing surgery
ithin 2 years after DES implantation. Bakhru et al. (23)
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)eported no stent thrombosis among 114 patients undergo- sng noncardiac surgery after a median of 236 days from stent
lacement.
Although stent thrombosis can occur before surgery
caused by cessation of antiplatelet therapy), most (24) stent
hromboses occur during or after the surgical procedure.
revention of Perioperative Stent Thrombosis
erioperative stent thrombosis could be prevented by: 1)
voiding preoperative revascularization; 2) revascularizing
atients without using stents; 3) appropriate selection of the
ype of stent to be implanted; 4) delaying surgery after stent
mplantation; 5) continuing antiplatelet therapy throughout
he perioperative period or only discontinuing it briefly; and
) improving awareness of this catastrophic complication
mong all physicians involved in the care of these patients
Fig. 1).
voiding preoperative revascularization. Many patients
ith coronary disease who require noncardiac surgery do not
enefit from preoperative revascularization. The CARP
Coronary Artery Revascularization Prophylaxis) trial en-
olled 510 stable patients with angiographic coronary artery
isease (one-third had 3-vessel disease) undergoing major
ascular surgery (33% abdominal aortic aneurysm repair and
7% lower extremity revascularization) (25). Patients with
ignificant left main disease, unstable coronary syndromes,
nd severe cardiomyopathy were excluded. Patients were
andomized to revascularization versus no revascularization
efore surgery. Revascularization was accomplished with
oronary bypass surgery in 41% and with PCI in 59%.
atients who did or did not undergo revascularization had a
imilar incidence of postoperative AMI (8.4% vs. 8.4%, p 
.99) and survival after a median of 27 months from
andomization (78% vs. 77%, p  0.98).
Therefore, if a patient with coronary disease is known to
equire surgery, the first question to ask is whether the
atient really needs revascularization. The CARP study
esults suggest that revascularization may not be necessary
or a large number of patients without an unstable coronary
yndrome or other very high-risk features. This is further
upported by the findings of a recent pilot study of 103
atients with extensive ischemia undergoing vascular sur-
ery, in whom preoperative revascularization did not im-
rove postoperative outcomes (26).
evascularization without stents (balloon only). Despite
he CARP study, many patients are believed to require
evascularization before noncardiac surgery, such as patients
ith acute coronary syndromes or with profound ischemia
n noninvasive testing at a heart rate and blood pressure
ikely to be exceeded in the perioperative period. Although
tents are currently used in the vast majority of PCIs,
oronary revascularization may be more safely performed in
uch patients without stents, either with coronary artery
ypass grafting or percutaneously with balloon angioplasty.
In an early study of 50 patients undergoing noncardiacurgery after a median of 9 days from balloon angioplasty,
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June 5, 2007:2145–50 Perioperative Management of Coronary Stentshe postoperative mortality and MI rates were 1.9% and
.6%, respectively (27). In a study of 194 patients undergo-
ng aortic abdominal surgery, carotid endarterectomy or
eripheral vascular surgery after a median time of 11 days
rom balloon angioplasty, only 1 patient died (0.5%) and 1
atient suffered an AMI (0.5%) (28). In the largest study, in
hich 350 patients underwent noncardiac surgery in the 2
onths after a successful balloon angioplasty procedure,
nly 3 of the 350 patients (0.9%, 95% CI 0.2% to 2.5%) died
n the perioperative period (n  1) or suffered a myocardial
nfarction (n  2) (29).
Therefore, revascularization with balloon angioplasty may
e safer than stent placement before planned noncardiac
urgery, especially if a good angiographic result can be
chieved, and particularly if the noncardiac surgery is
lanned early (within 4 to 6 weeks) after revascularization.
According to the 2002 American College of Cardiology/
merican Heart Association guidelines on perioperative
ardiovascular care, “there is uncertainty regarding how
uch time should pass before noncardiac surgery is per-
ormed” for patients undergoing preoperative balloon an-
ioplasty (1). Delaying noncardiac surgery for 6 to 8
eeks was discouraged because restenosis could have oc-
urred, leading to perioperative ischemia or MI. However,
erforming noncardiac surgery too early after the PCI also
ay be risky because acute or subacute closure after balloon
ngioplasty usually occurs within hours to days after the
rocedure. Accordingly, the guidelines emphasize that de-
aying surgery “for at least a week after balloon angioplasty
o allow for healing of the vessel injury at the balloon
reatment site has theoretical benefits.”
tent selection before surgery. Sometimes stenting cannot
e avoided during PCI, either because of the complexity of
Figure 1 Perioperative Stent Thrombosis Prevention Strategies
Outline of different strategies to prevent perioperative stent thrombosis. BMS  bhe lesion or because of the inability to achieve an optimal tesult with balloon angioplasty. The type of stent selected
hould be heavily influenced by the timing of surgery.
If surgery needs to be performed within 12 months
rom revascularization, then BMS implantation is likely
referable to DES, because BMS endothelialize more
apidly and may therefore carry a lower risk of stent
hrombosis. This is particularly likely if dual antiplatelet
herapy cannot be continued through the perioperative
eriod. If restenosis, which is more likely to occur after
MS than DES, does develop, it almost always does so
ore than 2 to 3 months after stent placement, at which
oint the patient already will have undergone the surgical
rocedure. At that time, a DES could be used to treat the
n-stent restenosis.
If surgery can be delayed for more than 12 months, then
lacement of a DES may not be inappropriate, although
here are data suggesting that DES may have a greater risk
f late stent thrombosis than BMS beyond 12 months after
mplantation, particularly in the perioperative period (19). If
lacement of a DES is planned, it may be preferable to use
sirolimus-eluting stent, which requires a minimum of 3
onths of clopidogrel after placement (30), than a
aclitaxel-eluting stent (PES), which requires at least 6
onths of clopidogrel (31). However, little is known about
he safety of surgery performed 6 to 12 months from DES
mplantation. An alternative approach would be placement
f a heparin-coated stent (which is not considered a DES
ecause the heparin does not elute off of the stent); such an
pproach is logical but unproven, because heparin-coated
tents have not been shown to reduce the frequency of stent
hrombosis in any situation with any medical regimen, let
lone in the perioperative period. In the future, new stent
ypes, such as bioresorbable stents or antibody-coated stents
tal stents; DES  drug-eluting stents; PCI  percutaneous coronary intervention.are-mehat can attract endothelial progenitor cells and re-
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Perioperative Management of Coronary Stents June 5, 2007:2145–50ndothelialize more rapidly, may minimize the risk of stent
hrombosis.
Regardless of the type of stent used, every effort should be
ade to optimally deploy the stent, which reduces the risk
f stent thrombosis (4,6). Overlap of DES should be
voided because overlapping may delay their endotheli-
lization significantly (32,33).
elay of surgery. The earlier the surgery is performed after
tenting, the higher the risk for stent thrombosis (14–17).
ccording to the American College of Cardiology/
merican Heart Association guidelines, noncardiac surgery
hould be “delayed for at least 2 and ideally 4 weeks after
MS implantation to allow for at least partial endotheli-
lization of the stent” (1). The best data suggest that
elaying surgery for 6 weeks may be even better than 4
eeks (15). The optimal delay after implantation of a DES
efore surgery remains unknown but is likely to be more
han 12 months (Fig. 1), particularly if antiplatelet therapy
ust be discontinued for the surgical procedure.
ntiplatelet therapy in the perioperative period. Dual
ntiplatelet therapy is the cornerstone of stent thrombosis
revention (11). The current recommendations that clopi-
ogrel be administered for 3 months after placement of an
ES and 6 months after placement of a PES are based on
he duration of time that a thienopyridine was required in
he pivotal trials of these stents that led to their approval;
hose durations were largely chosen empirically. Although
n observational study showed reduced risk of death or MI
hen clopidogrel was continued up to 2 years after DES
mplantation (34), the optimal duration of clopidogrel
equired to prevent late DES thrombosis is unknown.
Antiplatelet treatment strategies to minimize periopera-
ive stent thrombosis include:
Continue dual antiplatelet therapy during and after
surgery
Discontinue clopidogrel but “bridge” the patient to sur-
gery using a short-acting antiplatelet agent with a glyco-
protein IIb/IIIa inhibitor or an antithrombin, and restart
clopidogrel as soon as possible after surgery
Discontinue clopidogrel before surgery and restart it as
soon as possible after surgery
ONTINUE DUAL ANTIPLATELET THERAPY DURING SUR-
ERY. This option would likely be associated with the
owest frequency of stent thrombosis, especially in patients
ndergoing surgery early after stent implantation. Surgeons
ho are concerned about the risk of perioperative bleeding
ay need help weighing the risk of bleeding with the
articular operation planned against the benefits of continu-
ng dual antiplatelet therapy throughout the perioperative
eriod. In some procedures, such as dental extractions (35),
ataract surgery (36), or routine dermatologic surgery (37),
leeding almost always can be controlled with local mea-
ures, and discontinuation of antiplatelet therapy is not
ecessary (38). Even in procedures with higher bleeding
isk, when surgeons are informed that stent thrombosis peads to death or a large MI in the majority of patients (39),
nd that the best available data suggest a greatly increased
isk of stent thrombosis in patients undergoing surgery
hortly after stent placement when dual antiplatelet therapy
s discontinued, they often can be persuaded that the risk of
hrombosis outweighs the risk of bleeding. This strategy
ould not be appropriate for patients in whom any excess
leeding could have catastrophic consequences, such as
eurosurgery patients.
TOP CLOPIDOGREL AND “BRIDGE” THE PATIENT WITH A
HORT-ACTING ANTIPLATELET OR ANTITHROMBOTIC
GENT. Thienopyridines cause irreversible platelet inhibi-
ion, and need to be discontinued for 5 to 10 days to allow
he production and release into the circulation of new
latelets to replace the inhibited platelets and restore normal
emostasis. If surgery is needed early after stent placement
nd clopidogrel needs to be stopped, some clinicians
bridge” the patient to surgery using a short-acting anti-
latelet agent or an anticoagulant. Because stent thrombosis
s primarily a platelet-mediated phenomenon, platelet in-
ibitors might be a more logical choice if such a strategy is
ursued. Furthermore, the cessation of heparin in a patient
ot on aspirin or other antiplatelet agents has been shown to
ause platelet activation and a rebound phenomenon which
ay actually increase the likelihood of perioperative stent
hrombosis compared to if no heparin bridging had been
erformed. However, it must be emphasized that admitting
patient to a hospital before surgery to bridge them to
urgery does not offer complete protection because the
reatest risk of stent thrombosis is actually during or after
urgery. More data are needed that indicate that such a
trategy improves outcome because this strategy is expen-
ive, is logistically difficult, and exposes the patient to the
isks associated with a prolonged hospitalization.
TOP CLOPIDOGREL AND RESTART IT AFTER SURGERY.
his strategy may be sufficient when the stent is believed to
e fully endothelialized and the risk of stent thrombosis is
ery low. It also should be used whenever clopidogrel cannot
e continued throughout the perioperative period, such as in
atients undergoing neurosurgery, in whom bleeding would
ikely be catastrophic. There is variability in the rate at
hich DES are re-endothelialized, and the risk of stent
hrombosis may persist in some patients for many months or
onger, especially in the prothrombotic state induced by
urgery (19). Once the surgeon permits the re-initiation of
lopidogrel, it might be wisest to administer a 600-mg
oading, which not only reduces the time required to achieve
aximal inhibition of platelet aggregation to 2 to 4 h, but
lso reduces the frequency of hyporesponsiveness to clopi-
ogrel, particularly among patients with activated platelets
s is uniformly the case among patients who have just
ndergone surgery.
The aforementioned recommendations are largely em-iric and are based on indirect data, but they are mechanis-
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June 5, 2007:2145–50 Perioperative Management of Coronary Stentsically sound and logical, and the consequences of periop-
rative stent thrombosis are severe.
ducation and a team approach. Given the morbidity and
ortality associated with stent thrombosis, there is a need
or continuing education of physicians, particularly noncar-
iologists, about the perioperative risks of patients with
oronary stents. The need to delay elective surgery whenever
ossible after stent implantation cannot be overemphasized.
n a survey of anesthesiologists, 63% were not aware of
ecommendations about the appropriate length of time
etween stent placement and a subsequent surgical proce-
ure, and one-third recommended no delay or a delay of
nly 1 to 2 weeks, which is insufficient for BMS, and even
ore so for DES (40).
Anesthesiologists and surgeons should be alerted to the
igh risk of stent thrombosis in patients who have received
oronary stents (41). They should:
Determine the type (BMS, SES, PES) and location in
the coronary circulation of stents placed in their patient,
and the date of implantation
Consult with an interventional cardiologist and, when-
ever possible, with the patient’s cardiologist
Arrive at a joint decision with input from anesthesiolo-
gists, cardiologists, and surgeons about the timing of
surgery and the most appropriate management of the
patient’s antiplatelet regimen
Ideally, perform surgery in centers with 24-h interven-
tional cardiology coverage so that stent thrombosis, if it
occurs, could be treated with immediate PCI
reatment of Perioperative Stent Thrombosis
tent thrombosis is most often manifest as an ST-segment
levation acute myocardial infarction, and is best treated
ith early reperfusion. Thrombolytic therapy is less effective
t restoring reperfusion than primary PCI among all pa-
ients and—although unproven—may be even less effective
mong patients with stent thrombosis, which is a platelet-
ediated phenomenon. Moreover, thrombolytic therapy
ften carries a prohibitive risk of bleeding in the perioper-
tive period. Primary PCI is, therefore, the treatment of
hoice for perioperative stent thrombosis, although it also
arries increased risk of bleeding when performed early after
urgery because antithrombin and antiplatelet agents need
o be administered during the procedure. Yet, all that is
equired in patients with an acute coronary occlusion caused
y stent thrombosis or any other cause who are at increased
isk of bleeding is aspirin and 1 dose of an anticoagulant
uch as heparin or bivalirudin. In a retrospective analysis of
8 patients with acute myocardial infarction occurring
ithin 1 week from surgery in whom aspirin and heparin
ere administered, survival with an early invasive strategy
as 65%, which is encouraging given the high frequency of
ardiogenic shock and cardiac arrest in the study population
42). Only 1 patient had significant bleeding at the operative
ite, a patient who had undergone knee replacement. Pa-ients who had recently had brain and thoracic surgery were
ncluded in this series.
onclusions
erioperative coronary stent thrombosis is a catastrophic
ccurrence. The risk of stent thrombosis seems to be low
hen surgery is delayed for at least 4 to 6 weeks after
mplantation of a BMS. The risk of stent thrombosis after
ES implantation remains poorly studied, but may occur
ven in patients who have completed the recommended
uration of antiplatelet therapy (3 months for SES and 6
onths for PES) and subsequently undergo surgery, in most
ases after stopping aspirin and clopidogrel.
If major noncardiac surgery is planned within 1 month
nd certainly within 2 weeks, stent implantation generally
hould be avoided. If revascularization is required, then
alloon angioplasty or coronary bypass surgery might well
e preferred options. If surgery is planned between 1 and 12
onths, particularly if complex anatomy is present, then
MS implantation may be preferable. If surgery is planned
fter 12 months, DES implantation may be an acceptable
ption. Awareness, prevention, and early treatment of
erioperative stent thrombosis are best achieved by collab-
ration between surgeons, anesthesiologists, and cardiolo-
ists.
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